Bioventus (NASDAQ:BVS) Reaches New 12-Month High – Should You Buy?

Posted by Geri Gentry on Jul 6th, 2026

Shares of Bioventus Inc. (NASDAQ:BVS – Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $11.81 and last traded at $11.7430, with a volume of 320222 shares trading hands. The stock had previously closed at $10.48.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research report on Tuesday, June 16th. Barrington Research restated an “outperform” rating and set a $14.00 price objective on shares of Bioventus in a research note on Tuesday, June 30th. Finally, CJS Securities assumed coverage on Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $14.20.

Get Our Latest Stock Analysis on Bioventus

Bioventus Stock Up 12.0%

The company has a 50-day moving average of $9.53 and a 200-day moving average of $8.84. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $980.51 million, a price-to-earnings ratio of 28.69, a price-to-earnings-growth ratio of 1.35 and a beta of 0.65.

Bioventus (NASDAQ:BVS – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The company had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities analysts predict that Bioventus Inc. will post 0.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bioventus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Bioventus by 17,156.2% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after buying an additional 5,490 shares during the period. SG Americas Securities LLC purchased a new position in Bioventus during the fourth quarter valued at approximately $80,000. Diversified Trust Co purchased a new position in Bioventus during the first quarter valued at approximately $100,000. Prelude Capital Management LLC acquired a new position in Bioventus in the third quarter valued at approximately $74,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Bioventus in the 3rd quarter worth approximately $78,000. 62.94% of the stock is owned by institutional investors and hedge funds.

About Bioventus

(Get Free Report)

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.